SAN DIEGO and SUZHOU, China, Dec 14 (Bernama-GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced preclinical data demonstrating the compelling differentiation of ADG153, an anti-CD47 monoclonal antibody (mAb), and ADG152, a CD20xCD3 bispecific T-cell engager (TCE). The data were presented in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition taking place December 11-14, 2021, which are available in the Publications section of the company’s website at www.adagene.com.
http://mrem.bernama.com/viewsm.php?idm=41919
- UN: Plastic pollution treaty talks end without deal
- Tanzania: Pres Samia awarded for promoting sports, fostering peace through sports
- Kenya and Iran sign MoUs, vow to strengthen relations
- UN reports sharp rise in conflict-related sexual violence in 2024
- US sanctions Brazil health officials over Cuba’s overseas medical missions
- Bangladesh’s General Election Roadmap To Be Announced Next Week
- Two Injured In Israeli Airstrikes On Hezbollah Sites In Southern Lebanon
- Israeli Minister Announces 3,401 New Housing Units For Settlers, Expanding Illegal Housing In West Bank
- Kyrgyzstan, Afghanistan Agree To Boost Trade Cooperation
- Lebanese President Rejects Meddling, Urges Unity, In Talks With Iranian Envoy